ROCO
4188
Market cap27mUSD
Oct 08, Last price
13.95TWD
1D
0.00%
1Q
30.37%
Jan 2017
-54.41%
IPO
-75.64%
Name
AmCad BioMed Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UB, an AI Solution for Breast Lesion Detection. The company was incorporated in 2008 and is based in Taipei City, Taiwan.
Key people
Chairman of the Board, General Manager · since 2024
Vice Chairman of the Board · since 2020
Junlin Li
Deputy General Manager-Exhibition Industry · since 2017
Josh Chen
Head of Finance · since 2025
Danica Dai
Head of Finance & Accounting · since 2025
Zhiyuan Huang
Corporate Governance Officer · since 2024
Weide Chen
Director · since 2019
Director · since 2020
Shuti Qiu
Director · since 2020
Director · since 2020
Zaibin Wang
Director · since 2023
Jinchuan Xu
Director · since 2014
Director · since 2014
Independent Director · since 2020
Xueyu Li
Independent Director · since 2023
Seyi Lin
Independent Director · since 2023
Qingtian Zhang
Independent Director · since 2017
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||